Schrödinger (SDGR) Competitors

Schrödinger (NASDAQ:SDGR) and Emergent BioSolutions (NYSE:EBS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

Which has more volatility and risk, SDGR or EBS?

Schrödinger has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Comparatively, Emergent BioSolutions has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500.

Is SDGR or EBS more profitable?

Emergent BioSolutions has a net margin of -18.55% compared to Schrödinger's net margin of -91.84%. Emergent BioSolutions' return on equity of -9.91% beat Schrödinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Schrödinger	-91.84%	-35.77%	-24.51%
Emergent BioSolutions	-18.55%	-9.91%	-3.31%

Does the MarketBeat Community believe in SDGR or EBS?

Emergent BioSolutions received 367 more outperform votes than Schrödinger when rated by MarketBeat users. Likewise, 66.77% of users gave Emergent BioSolutions an outperform vote while only 56.99% of users gave Schrödinger an outperform vote.

Company	Underperform	Outperform
Schrödinger	Outperform Votes 53 56.99%	Underperform Votes 40 43.01%
Emergent BioSolutions	Outperform Votes 420 66.77%	Underperform Votes 209 33.23%

Do insiders and institutionals believe in SDGR or EBS?

79.1% of Schrödinger shares are held by institutional investors. Comparatively, 78.4% of Emergent BioSolutions shares are held by institutional investors. 8.6% of Schrödinger shares are held by company insiders. Comparatively, 1.2% of Emergent BioSolutions shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Do analysts recommend SDGR or EBS?

Schrödinger presently has a consensus price target of $32.90, indicating a potential upside of 71.62%. Emergent BioSolutions has a consensus price target of $14.00, indicating a potential upside of 57.66%. Given Schrödinger's higher possible upside, equities analysts clearly believe Schrödinger is more favorable than Emergent BioSolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrödinger	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.82
Emergent BioSolutions	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has stronger valuation and earnings, SDGR or EBS?

Schrödinger has higher earnings, but lower revenue than Emergent BioSolutions. Schrödinger is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrödinger	$216.67M	6.44	$40.72M	-$2.34	-8.19
Emergent BioSolutions	$1.09B	0.44	-$760.50M	-$4.10	-2.17

Does the media refer more to SDGR or EBS?

In the previous week, Schrödinger had 7 more articles in the media than Emergent BioSolutions. MarketBeat recorded 10 mentions for Schrödinger and 3 mentions for Emergent BioSolutions. Schrödinger's average media sentiment score of 0.47 beat Emergent BioSolutions' score of 0.15 indicating that Schrödinger is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Schrödinger	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Emergent BioSolutions	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Schrödinger beats Emergent BioSolutions on 10 of the 19 factors compared between the two stocks.